{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:07:49Z","timestamp":1793423269799,"version":"4.5.0"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>RNA-based therapeutics, such as small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs) and messenger RNAs (mRNAs) are promising therapeutics that offer new avenues for targeting molecular pathways underlying heart failure (HF) pathogenesis. This review provides an overview of RNA therapeutics, detailing their mechanisms and potential applications in the treatment of HF. Key pathological processes in HF, including dysregulated calcium handling, myocardial fibrosis, oxidative stress, inflammation and aberrant signalling, are explored to identify how RNA-based therapeutics can be utilized to address these mechanisms. Preclinical studies demonstrating the potential of RNA therapeutics to modulate these pathways are discussed. In addition, the review identifies novel therapeutic targets of HF that may allow more precise and effective interventions, potentially reversing disease progression in HF. In this way, the potential of RNA therapeutics as a next-generation treatment strategy for HF are highlighted, offering hope for more targeted and personalized approaches for HF.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s12265-025-10717-9","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:42:14Z","timestamp":1761831734000},"page":"1540-1554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["RNA Therapeutics in Heart Failure"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9793-4683","authenticated-orcid":false,"given":"Frederik E.","family":"Deiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrthe M.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman H. W.","family":"Sillje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Grote Beverborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Bomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-4413","authenticated-orcid":false,"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"10717_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","volume":"8","author":"AL Bui","year":"2011","unstructured":"Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30\u201341.","journal-title":"Nat Rev Cardiol"},{"key":"10717_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.21037\/cdt-20-302","volume":"11","author":"RHG Schwinger","year":"2021","unstructured":"Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021;11:263.","journal-title":"Cardiovasc Diagn Ther"},{"key":"10717_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"10717_CR4","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2023114760","volume":"42","author":"A Sparmann","year":"2023","unstructured":"Sparmann A, Vogel J. RNA -based medicine: from molecular mechanisms to therapy. EMBO J. 2023;42: e114760.","journal-title":"EMBO J."},{"key":"10717_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/HCO.0000000000000850","volume":"36","author":"C Boada","year":"2021","unstructured":"Boada C, Sukhovershin R, Pettigrew R, Cooke JP. RNA therapeutics for cardiovascular disease. Curr Opin Cardiol. 2021;36:256.","journal-title":"Curr Opin Cardiol"},{"key":"10717_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1161\/CIRCRESAHA.117.311311","volume":"123","author":"T Lucas","year":"2018","unstructured":"Lucas T, Bonauer A, Dimmeler S. RNA therapeutics in cardiovascular disease. Circ Res. 2018;123:205\u201320.","journal-title":"Circ Res"},{"key":"10717_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00953","volume":"9","author":"A Laina","year":"2018","unstructured":"Laina A, Gatsiou A, Georgiopoulos G, Stamatelopoulos K, Stellos K. RNA therapeutics in cardiovascular precision medicine. Front Physiol. 2018;9:386417.","journal-title":"Front Physiol"},{"key":"10717_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1161\/CIRCULATIONAHA.123.067373","volume":"149","author":"VJ Dzau","year":"2024","unstructured":"Dzau VJ, Hodgkinson CP. RNA therapeutics for the cardiovascular system. Circulation. 2024;149:707\u201316.","journal-title":"Circulation"},{"issue":"11","key":"10717_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41569-019-0218-x","volume":"16","author":"D Lu","year":"2019","unstructured":"Lu D, Thum T. RNA-based diagnostic and therapeutic strategies for cardiovascular disease. Nat Rev Cardiol. 2019;16(11):661\u201374.","journal-title":"Nat Rev Cardiol"},{"key":"10717_CR10","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/eurjpc\/zwac179","volume":"29","author":"AB Gevaert","year":"2022","unstructured":"Gevaert AB, et al. Epigenetics in the primary and secondary prevention of cardiovascular disease: influence of exercise and nutrition. Eur J Prev Cardiol. 2022;29:2183\u201399.","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"10717_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-05075-2","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhu L, Wang X, Jin H. RNA-based therapeutics: an overview and prospectus. Cell Death Dis. 2022;13(7):1\u201315.","journal-title":"Cell Death Dis"},{"key":"10717_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1124\/jpet.122.001234","volume":"384","author":"GM Traber","year":"2023","unstructured":"Traber GM, Yu AM. RNAi-based therapeutics and novel RNA bioengineering technologies. J Pharmacol Exp Ther. 2023;384:133\u201354.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10717_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2017","unstructured":"Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2017;14(1):9\u201321.","journal-title":"Nat Rev Neurol"},{"key":"10717_CR14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","volume":"136","author":"RW Carthew","year":"2009","unstructured":"Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136:642\u201355.","journal-title":"Cell"},{"key":"10717_CR15","first-page":"141","volume":"629","author":"CB Moore","year":"2010","unstructured":"Moore CB, Guthrie EH, Huang MTH, Taxman DJ. Short Hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol Biol. 2010;629:141.","journal-title":"Methods Mol Biol"},{"issue":"11","key":"10717_CR16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/nbt.2413","volume":"30","author":"M Elsner","year":"2012","unstructured":"Elsner M. Single-stranded siRNAs for in vivo gene silencing. Nat Biotechnol. 2012;30(11):1063\u20131063.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10717_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrd3141","volume":"9","author":"AD Keefe","year":"2010","unstructured":"Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(7):537\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"10717_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim KRQ, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533\u201345.","journal-title":"Drug Des Devel Ther"},{"key":"10717_CR19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ. Inotersen: First global approval. Drugs. 2018;78:1371\u20136.","journal-title":"Drugs"},{"key":"10717_CR20","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1002\/ehf2.14516","volume":"10","author":"V Wagh","year":"2023","unstructured":"Wagh V, et al. Circulating micrornas and cardiomyocyte proliferation in heart failure patients related to 10 years survival. ESC Heart Fail. 2023;10:3559\u201372.","journal-title":"ESC Heart Fail"},{"key":"10717_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1101\/gad.981002","volume":"16","author":"PJ Paddison","year":"2002","unstructured":"Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002;16:948.","journal-title":"Genes Dev"},{"key":"10717_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","volume":"150","author":"D Yu","year":"2012","unstructured":"Yu D, et al. Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression. Cell. 2012;150:895\u2013908.","journal-title":"Cell"},{"key":"10717_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2012.08.014","volume":"150","author":"WF Lima","year":"2012","unstructured":"Lima WF, et al. Single-stranded siRNAs activate RNAi in animals. Cell. 2012;150:883\u201394.","journal-title":"Cell"},{"key":"10717_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107659","volume":"213","author":"B Xia","year":"2025","unstructured":"Xia B, et al. RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases. Pharmacol Res. 2025;213:107659.","journal-title":"Pharmacol Res"},{"key":"10717_CR25","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/clinchem\/45.9.1628","volume":"45","author":"SD Jayasena","year":"1999","unstructured":"Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem. 1999;45:1628\u201350.","journal-title":"Clin Chem"},{"issue":"1","key":"10717_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01007-w","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin S, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Targeted Ther. 2022;7(1):1\u201335.","journal-title":"Signal Transduct Targeted Ther"},{"issue":"11","key":"10717_CR27","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat Biotechnol. 2022;40(11):1586\u2013600.","journal-title":"Nat Biotechnol"},{"key":"10717_CR28","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet. 2024;403:1192\u2013204.","journal-title":"Lancet"},{"key":"10717_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/d41573-021-00127-2","volume":"20","author":"K Kingwell","year":"2021","unstructured":"Kingwell K. Small activating RNAs lead the charge to turn up gene expression. Nat Rev Drug Discov. 2021;20:573\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10717_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41580-022-00566-8","volume":"24","author":"JS Mattick","year":"2023","unstructured":"Mattick JS, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430\u201347.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10717_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","volume":"41","author":"R Chen","year":"2022","unstructured":"Chen R, et al. Engineering circular RNA for enhanced protein production. Nat Biotechnol. 2022;41(2):262\u201372.","journal-title":"Nat Biotechnol"},{"key":"10717_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/ncrna7040065","volume":"7","author":"CC Martins Correia","year":"2021","unstructured":"Martins Correia CC, Rodrigues LF, De Avila Pelozin BR, Oliveira EM, Fernandes T. Long non-coding RNAs in cardiovascular diseases: potential function as biomarkers and therapeutic targets of exercise training. Non-Coding RNA. 2021;7:65.","journal-title":"Non-Coding RNA"},{"key":"10717_CR33","first-page":"3","volume":"10","author":"S Jha","year":"2024","unstructured":"Jha S, ThasmaLoganathbabu VK, Kumaran K, Krishnasamy G, Aruljothi KN. Long non-coding RNAs (lncRNAs) in heart failure: a comprehensive review. Noncoding RNA. 2024;10:3.","journal-title":"Noncoding RNA"},{"key":"10717_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115302","volume":"208","author":"P Gil-Cabrerizo","year":"2024","unstructured":"Gil-Cabrerizo P, Simon-Yarza T, Garbayo E, Blanco Prieto MJ. Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics. Adv Drug Deliv Rev. 2024;208:115302.","journal-title":"Adv Drug Deliv Rev"},{"key":"10717_CR35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/stcltm\/szad038","volume":"12","author":"M Giacca","year":"2023","unstructured":"Giacca M. Fulfilling the promise of RNA therapies for cardiac repair and regeneration. Stem Cells Transl Med. 2023;12:527.","journal-title":"Stem Cells Transl Med"},{"key":"10717_CR36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/joim.13308","volume":"290","author":"H Korpela","year":"2021","unstructured":"Korpela H, et al. Gene therapy for ischaemic heart disease and heart failure. J Intern Med. 2021;290:567\u201382.","journal-title":"J Intern Med"},{"key":"10717_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2023.101636","volume":"70","author":"N Vora","year":"2024","unstructured":"Vora N, et al. Gene therapy for heart failure: a novel treatment for the age old disease. Dis-a-Mon. 2024;70:101636.","journal-title":"Dis-a-Mon"},{"key":"10717_CR38","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","volume":"27","author":"AG von Orlandini Niessen","year":"2019","unstructured":"von Orlandini Niessen AG, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2019 UTRs identified by cellular library screening. Mol Ther. 2019;27:824\u201336.","journal-title":"Mol Ther"},{"key":"10717_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s12471-025-01941-8","volume":"33","author":"FE Deiman","year":"2025","unstructured":"Deiman FE, et al. Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohort. Neth Heart J. 2025;33:112\u20139.","journal-title":"Neth Heart J."},{"key":"10717_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s11897-022-00558-x","volume":"19","author":"FE Deiman","year":"2022","unstructured":"Deiman FE, Bomer N, van der Meer P, Grote Beverborg N. Precision medicine approaches for genetic cardiomyopathy: targeting phospholamban R14del. Curr Heart Fail Rep. 2022;19:170\u20139.","journal-title":"Curr Heart Fail Rep"},{"key":"10717_CR41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","volume":"42","author":"J T\u00e4ubel","year":"2021","unstructured":"T\u00e4ubel J, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021;42:178\u201388.","journal-title":"Eur Heart J"},{"key":"10717_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389:228\u201338.","journal-title":"N Engl J Med"},{"key":"10717_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392:33\u201344.","journal-title":"N Engl J Med."},{"key":"10717_CR44","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430\u201340.","journal-title":"N Engl J Med"},{"key":"10717_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","volume":"64","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021;64:285\u201392.","journal-title":"Muscle Nerve"},{"key":"10717_CR46","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","volume":"31","author":"V Anttila","year":"2023","unstructured":"Anttila V, et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol Ther. 2023;31:866\u201374.","journal-title":"Mol Ther"},{"key":"10717_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22\u201331.","journal-title":"N Engl J Med"},{"key":"10717_CR48","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, et al. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507\u201319.","journal-title":"N Engl J Med"},{"key":"10717_CR49","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/CIRCRESAHA.113.301651","volume":"113","author":"M Luo","year":"2013","unstructured":"Luo M, Anderson ME. Mechanisms of altered Ca2+ handling in heart failure. Circ Res. 2013;113:690\u2013708.","journal-title":"Circ Res"},{"key":"10717_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.addr.2019.05.011","volume":"146","author":"S Hinderer","year":"2019","unstructured":"Hinderer S, Schenke-Layland K. Cardiac fibrosis \u2013 a short review of causes and therapeutic strategies. Adv Drug Deliv Rev. 2019;146:77\u201382.","journal-title":"Adv Drug Deliv Rev"},{"key":"10717_CR51","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1177\/2047487319870344","volume":"27","author":"A Aimo","year":"2020","unstructured":"Aimo A, et al. Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 2020;27:494\u2013510.","journal-title":"Eur J Prev Cardiol"},{"key":"10717_CR52","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1152\/ajpheart.00554.2011","volume":"301","author":"H Tsutsui","year":"2011","unstructured":"Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301:2181\u201390.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10717_CR53","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","volume":"75","author":"SP Murphy","year":"2020","unstructured":"Murphy SP, Kakkar R, McCarthy CP, Januzzi JL. Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:1324\u201340.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10717_CR54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","volume":"17","author":"L Adamo","year":"2020","unstructured":"Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17(5):269\u201385.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10717_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-25439-0","volume":"12","author":"N Grote Beverborg","year":"2021","unstructured":"Grote Beverborg N, et al. Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy. Nat Commun. 2021;12(1):1\u201315.","journal-title":"Nat Commun"},{"key":"10717_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1144069","volume":"14","author":"S Zaveri","year":"2023","unstructured":"Zaveri S, Srivastava U, Qu YS, Chahine M, Boutjdir M. Pathophysiology of Cav1.3 L-type calcium channels in the heart. Front Physiol. 2023;14:1144069.","journal-title":"Front Physiol"},{"key":"10717_CR57","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1152\/physrev.00029.2007","volume":"89","author":"S Dai","year":"2009","unstructured":"Dai S, Hall DD, Hell JW. Supramolecular assemblies and localized regulation of voltage-gated ion channels. Physiol Rev. 2009;89:411\u201352.","journal-title":"Physiol Rev"},{"key":"10717_CR58","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2174\/138945011795378559","volume":"12","author":"C Pott","year":"2011","unstructured":"Pott C, Eckardt L, Goldhaber IJ. Triple threat: The Na+\/Ca2+ exchanger in the pathophysiology of cardiac arrhythmia, ischemia and heart failure. Curr Drug Targets. 2011;12:737.","journal-title":"Curr Drug Targets"},{"key":"10717_CR59","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/CIRCRESAHA.113.301781","volume":"113","author":"S Weiss","year":"2013","unstructured":"Weiss S, Oz S, Benmocha A, Dascal N. Regulation of cardiac L-type Ca2+ channel CaV1.2 via the \u03b2-adrenergic-cAMP-protein kinase a pathway: old dogmas, advances, and new uncertainties. Circ Res. 2013;113:617\u201331.","journal-title":"Circ Res"},{"key":"10717_CR60","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1161\/CIRCRESAHA.114.300568","volume":"114","author":"D Dobrev","year":"2014","unstructured":"Dobrev D, Wehrens XHT. Role of RyR2 phosphorylation in heart failure and arrhythmias: Controversies around ryanodine receptor phosphorylation in cardiac disease. Circ Res. 2014;114:1311\u20139.","journal-title":"Circ Res"},{"key":"10717_CR61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.yjmcc.2013.06.001","volume":"61","author":"M Ottolia","year":"2013","unstructured":"Ottolia M, Torres N, Bridge JHB, Philipson KD, Goldhaber JI. Na\/Ca exchange and contraction of the heart. J Mol Cell Cardiol. 2013;61:28.","journal-title":"J Mol Cell Cardiol"},{"key":"10717_CR62","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1161\/01.CIR.0000095274.72486.94","volume":"108","author":"CR Weber","year":"2003","unstructured":"Weber CR, Piacentino V, Houser SR, Bers DM. Dynamic regulation of sodium\/calcium exchange function in human heart failure. Circulation. 2003;108:2224\u20139.","journal-title":"Circulation"},{"key":"10717_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddmec.2010.07.005","volume":"7","author":"H Schulman","year":"2010","unstructured":"Schulman H, Anderson ME. Ca2+\/calmodulin-dependent protein kinase II in heart failure. Drug Discov Today Dis Mech. 2010;7:e117.","journal-title":"Drug Discov Today Dis Mech"},{"key":"10717_CR64","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/cvr\/cvab008","volume":"118","author":"Y Liu","year":"2022","unstructured":"Liu Y, Chen J, Fontes SK, Bautista EN, Cheng Z. Physiological and pathological roles of protein kinase A in the heart. Cardiovasc Res. 2022;118:386\u201398.","journal-title":"Cardiovasc Res"},{"key":"10717_CR65","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.yjmcc.2011.01.012","volume":"51","author":"ME Anderson","year":"2011","unstructured":"Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51:468\u201373.","journal-title":"J Mol Cell Cardiol"},{"key":"10717_CR66","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3892\/etm.2017.4034","volume":"13","author":"P Zhang","year":"2017","unstructured":"Zhang P. CaMKII: the molecular villain that aggravates cardiovascular disease. Exp Ther Med. 2017;13:815\u201320.","journal-title":"Exp Ther Med"},{"key":"10717_CR67","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.arcmed.2018.12.008","volume":"49","author":"NS Saad","year":"2019","unstructured":"Saad NS, Elnakish MT, Ahmed AAE, Janssen PML. Protein kinase A as a promising target for heart failure drug development. Arch Med Res. 2019;49:530.","journal-title":"Arch Med Res"},{"key":"10717_CR68","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1161\/hh2301.100003","volume":"89","author":"CL Antos","year":"2001","unstructured":"Antos CL, et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ Res. 2001;89:997\u20131004.","journal-title":"Circ Res"},{"key":"10717_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110203","volume":"90","author":"E Klapproth","year":"2022","unstructured":"Klapproth E, K\u00e4mmerer S, El-Armouche A. Function and regulation of phosphatase 1 in healthy and diseased heart. Cell Signal. 2022;90:110203.","journal-title":"Cell Signal"},{"key":"10717_CR70","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jacc.2007.12.014","volume":"51","author":"Y Kawase","year":"2008","unstructured":"Kawase Y, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008;51:1112\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"10717_CR71","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1073\/pnas.97.2.793","volume":"97","author":"MI Miyamoto","year":"2000","unstructured":"Miyamoto MI, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A. 2000;97:793\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10717_CR72","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","volume":"387","author":"B Greenberg","year":"2016","unstructured":"Greenberg B, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387:1178\u201386.","journal-title":"Lancet"},{"key":"10717_CR73","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38319","volume":"7","author":"CA Makarewich","year":"2018","unstructured":"Makarewich CA, et al. The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy. Elife. 2018;7: e38319.","journal-title":"Elife."},{"key":"10717_CR74","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrm1151","volume":"4","author":"DH MacLennan","year":"2003","unstructured":"MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566\u201377.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10717_CR75","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1161\/01.CIR.101.18.2193","volume":"101","author":"K Eizema","year":"2000","unstructured":"Eizema K, et al. Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation. 2000;101:2193\u20139.","journal-title":"Circulation"},{"issue":"351","key":"10717_CR76","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.aad4076","volume":"1979","author":"BR Nelson","year":"2016","unstructured":"Nelson BR, et al. Muscle physiology: A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. Science. 2016;1979(351):271\u20135.","journal-title":"Science"},{"key":"10717_CR77","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.120.317156","volume":"127","author":"CA Makarewich","year":"2020","unstructured":"Makarewich CA, Bezprozvannaya S, Gibson AM, Bassel-Duby R, Olson EN. Gene therapy with the DWORF micropeptide attenuates cardiomyopathy in mice. Circ Res. 2020;127:1340\u20132.","journal-title":"Circ Res"},{"key":"10717_CR78","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1161\/CIRCRESAHA.123.323304","volume":"133","author":"NM Stege","year":"2023","unstructured":"Stege NM, et al. DWORF extends life span in a PLN-R14del cardiomyopathy mouse model by reducing abnormal sarcoplasmic reticulum clusters. Circ Res. 2023;133:1006\u201321.","journal-title":"Circ Res"},{"issue":"2","key":"10717_CR79","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000078","volume":"2","author":"I Karakikes","year":"2013","unstructured":"Karakikes I, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc. 2013;2(2): e000078.","journal-title":"J Am Heart Assoc."},{"key":"10717_CR80","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.acvd.2015.07.003","volume":"108","author":"G Sygitowicz","year":"2015","unstructured":"Sygitowicz G, et al. Circulating microribonucleic acids miR-1, miR-21 and miR-208a in patients with symptomatic heart failure: preliminary results. Arch Cardiovasc Dis. 2015;108:634\u201342.","journal-title":"Arch Cardiovasc Dis"},{"key":"10717_CR81","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/cvr\/cvs196","volume":"95","author":"J Ai","year":"2012","unstructured":"Ai J, et al. Overexpression of microRNA-1 impairs cardiac contractile function by damaging sarcomere assembly. Cardiovasc Res. 2012;95:385\u201393.","journal-title":"Cardiovasc Res"},{"key":"10717_CR82","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nature13073","volume":"508","author":"C Wahlquist","year":"2014","unstructured":"Wahlquist C, et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature. 2014;508:531\u20135.","journal-title":"Nature"},{"key":"10717_CR83","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCRESAHA.109.212183","volume":"106","author":"M Abdellatif","year":"2010","unstructured":"Abdellatif M. The role of miR-133 in cardiac hypertrophy uncovered. Circ Res. 2010;106:16.","journal-title":"Circ Res"},{"key":"10717_CR84","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.121.055866","volume":"144","author":"J Modica","year":"2021","unstructured":"Modica J, et al. Nano-miR-133a replacement therapy blunts pressure overload-induced heart failure. Circulation. 2021;144:1973\u20136.","journal-title":"Circulation"},{"key":"10717_CR85","volume":"9","author":"N Li","year":"2018","unstructured":"Li N, Zhou H, Tang Q. MiR-133: a suppressor of cardiac remodeling? Front Pharmacol. 2018;9:371516.","journal-title":"Front Pharmacol"},{"key":"10717_CR86","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.yjmcc.2021.02.009","volume":"155","author":"SM Mijailovich","year":"2021","unstructured":"Mijailovich SM, et al. The effect of variable troponin C mutation thin filament incorporation on cardiac muscle twitch contractions. J Mol Cell Cardiol. 2021;155:112\u201324.","journal-title":"J Mol Cell Cardiol"},{"key":"10717_CR87","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","volume":"23","author":"VS Moiseyev","year":"2002","unstructured":"Moiseyev VS, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422\u201332.","journal-title":"Eur Heart J"},{"key":"10717_CR88","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.addr.2019.05.011","volume":"146","author":"S Hinderer","year":"2019","unstructured":"Hinderer S, Schenke-Layland K. Cardiac fibrosis \u2013 a short review of causes and therapeutic strategies. Adv Drug Deliv Rev. 2019;146:77\u201382.","journal-title":"Adv Drug Deliv Rev"},{"key":"10717_CR89","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40119-020-00199-y","volume":"9","author":"M Webber","year":"2020","unstructured":"Webber M, Jackson SP, Moon JC, Captur G. Myocardial fibrosis in heart failure: anti-fibrotic therapies and the role of cardiovascular magnetic resonance in drug trials. Cardiol Ther. 2020;9:363\u201376.","journal-title":"Cardiol Ther"},{"key":"10717_CR90","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1096\/fj.03-0699com","volume":"18","author":"GR Grotendorst","year":"2004","unstructured":"Grotendorst GR, Rahmanie H, Duncan MR. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J. 2004;18:469\u201379.","journal-title":"FASEB J"},{"key":"10717_CR91","first-page":"269","volume":"15","author":"C Badid","year":"2000","unstructured":"Badid C, Mounier N, Costa AMA, Desmouli\u00e8re A. Role of myofibroblasts during normal tissue repair and excessive scarring: interest of their assessment in nephropathies. Histol Histopathol. 2000;15:269\u201380.","journal-title":"Histol Histopathol"},{"key":"10717_CR92","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1161\/CIRCRESAHA.115.305242","volume":"118","author":"EE Creemers","year":"2016","unstructured":"Creemers EE, Van Rooij E. Function and therapeutic potential of noncoding RNAs in cardiac fibrosis. Circ Res. 2016;118:108\u201318.","journal-title":"Circ Res"},{"key":"10717_CR93","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1111\/jcmm.13654","volume":"22","author":"X Zhou","year":"2018","unstructured":"Zhou X, et al. MiR-21 promotes cardiac fibroblast-to-myofibroblast transformation and myocardial fibrosis by targeting Jagged1. J Cell Mol Med. 2018;22:3816\u201324.","journal-title":"J Cell Mol Med"},{"key":"10717_CR94","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/ijc.25506","volume":"128","author":"Q Yao","year":"2011","unstructured":"Yao Q, et al. Micro-RNA-21 regulates TGF-\u03b2-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction. Int J Cancer. 2011;128:1783\u201392.","journal-title":"Int J Cancer"},{"key":"10717_CR95","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.biocel.2012.08.019","volume":"44","author":"H Liang","year":"2012","unstructured":"Liang H, et al. A novel reciprocal loop between microrna-21 and TGF\u03b2RIII is involved in cardiac fibrosis. Int J Biochem Cell Biol. 2012;44:2152\u201360.","journal-title":"Int J Biochem Cell Biol"},{"key":"10717_CR96","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1084\/jem.20100035","volume":"207","author":"G Liu","year":"2010","unstructured":"Liu G, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207:1589\u201397.","journal-title":"J Exp Med"},{"issue":"5","key":"10717_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12226","volume":"11","author":"R Bhome","year":"2022","unstructured":"Bhome R, et al. Epithelial to mesenchymal transition influences fibroblast phenotype in colorectal cancer by altering miR-200 levels in extracellular vesicles. J Extracell Vesicles. 2022;11(5): e12226.","journal-title":"J Extracell Vesicles."},{"key":"10717_CR98","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1111\/jcmm.13690","volume":"22","author":"YW Liao","year":"2018","unstructured":"Liao YW, Yu CC, Hsieh PL, Chang YC. miR-200b ameliorates myofibroblast transdifferentiation in precancerous oral submucous fibrosis through targeting ZEB2. J Cell Mol Med. 2018;22:4130\u20138.","journal-title":"J Cell Mol Med"},{"key":"10717_CR99","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.biopha.2018.01.158","volume":"100","author":"X Zhou","year":"2018","unstructured":"Zhou X, et al. Microrna-519d inhibits proliferation and induces apoptosis of human hypertrophic scar fibroblasts through targeting Sirtuin 7. Biomed Pharmacother. 2018;100:184\u201390.","journal-title":"Biomed Pharmacother"},{"key":"10717_CR100","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1083\/jcb.122.1.103","volume":"122","author":"A Desmouli\u00e8re","year":"1993","unstructured":"Desmouli\u00e8re A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103\u201311.","journal-title":"J Cell Biol"},{"key":"10717_CR101","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S1359-6101(97)00010-5","volume":"8","author":"GR Grotendorst","year":"1997","unstructured":"Grotendorst GR. Connective tissue growth factor: A mediator of TGf-\u03b2 action on fibroblasts. Cytokine Growth Factor Rev. 1997;8:171\u20139.","journal-title":"Cytokine Growth Factor Rev"},{"key":"10717_CR102","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1186\/1755-1536-5-S1-S24","volume":"5","author":"KE Lipson","year":"2012","unstructured":"Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5:S24.","journal-title":"Fibrogenesis Tissue Repair."},{"key":"10717_CR103","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1755-3768.2009.01641.x","volume":"88","author":"H Yang","year":"2010","unstructured":"Yang H, et al. The role of CTGF in the diabetic rat retina and its relationship with VEGF and TGF-\u03b2(2), elucidated by treatment with CTGFsiRNA. Acta Ophthalmol. 2010;88:652\u20139.","journal-title":"Acta Ophthalmol"},{"key":"10717_CR104","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/jcmm.12754","volume":"20","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, et al. Microrna-503 promotes angiotensin II-induced cardiac fibrosis by targeting Apelin-13. J Cell Mol Med. 2016;20:495\u2013505.","journal-title":"J Cell Mol Med"},{"key":"10717_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2023.111818","volume":"212","author":"SS Jankauskas","year":"2023","unstructured":"Jankauskas SS, et al. MiR-181c targets Parkin and SMAD7 in human cardiac fibroblasts: validation of differential microRNA expression in patients with diabetes and heart failure with preserved ejection fraction. Mech Ageing Dev. 2023;212:111818.","journal-title":"Mech Ageing Dev"},{"key":"10717_CR106","doi-asserted-by":"publisher","first-page":"1383046","DOI":"10.3389\/fcvm.2024.1383046","volume":"11","author":"JRA Boen","year":"2024","unstructured":"Boen JRA, et al. Divergent cardiac and renal effects of miR-181c-5p inhibition in a rodent heart failure model. Front Cardiovasc Med. 2024;11:1383046.","journal-title":"Front Cardiovasc Med"},{"key":"10717_CR107","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.114.014821","volume":"132","author":"S Araki","year":"2015","unstructured":"Araki S, et al. Sirt7 contributes to myocardial tissue repair by maintaining transforming growth factor-\u03b2 signaling pathway. Circulation. 2015;132:1081\u201393.","journal-title":"Circulation"},{"key":"10717_CR108","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.yjmcc.2018.07.251","volume":"121","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Shiok TC, Richards AM, Wang P. Microrna-101a suppresses fibrotic programming in isolated cardiac fibroblasts and in vivo fibrosis following trans-aortic constriction. J Mol Cell Cardiol. 2018;121:266\u201376.","journal-title":"J Mol Cell Cardiol"},{"key":"10717_CR109","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000369689","volume":"35","author":"X Zhao","year":"2015","unstructured":"Zhao X, et al. Microrna-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGF\u03b2RI on cardiac fibroblasts. Cell Physiol Biochem. 2015;35:213\u201326.","journal-title":"Cell Physiol Biochem"},{"key":"10717_CR110","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/cvr\/cvp130","volume":"83","author":"H Shan","year":"2009","unstructured":"Shan H, et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res. 2009;83:465\u201372.","journal-title":"Cardiovasc Res"},{"key":"10717_CR111","doi-asserted-by":"publisher","first-page":"78331","DOI":"10.18632\/oncotarget.13048","volume":"7","author":"WS Zhu","year":"2016","unstructured":"Zhu WS, et al. Targeting EZH1 and EZH2 contributes to the suppression of fibrosis-associated genes by miR-214-3p in cardiac myofibroblasts. Oncotarget. 2016;7:78331\u201342.","journal-title":"Oncotarget"},{"key":"10717_CR112","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/ar.23396","volume":"299","author":"H Dong","year":"2016","unstructured":"Dong H, et al. Microrna-214 exerts a cardio-protective effect by inhibition of fibrosis. Anat Rec (Hoboken). 2016;299:1348\u201357.","journal-title":"Anat Rec (Hoboken)"},{"key":"10717_CR113","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.matbio.2018.01.013","volume":"68\u201369","author":"L Li","year":"2018","unstructured":"Li L, Zhao Q, Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol. 2018;68\u201369:490\u2013506.","journal-title":"Matrix Biol"},{"key":"10717_CR114","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","volume":"117","author":"NG Frangogiannis","year":"2021","unstructured":"Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117:1450\u201388.","journal-title":"Cardiovasc Res"},{"key":"10717_CR115","doi-asserted-by":"crossref","unstructured":"Nagase H. Zinc metalloproteases in health and disease, matrix metalloproteinases. 1996;173\u2013224.","DOI":"10.1201\/9781482272765-16"},{"key":"10717_CR116","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/rr126","volume":"2","author":"WC Parks","year":"2001","unstructured":"Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res. 2001;2:10\u20139.","journal-title":"Respir Res"},{"key":"10717_CR117","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/01.CIR.98.17.1728","volume":"98","author":"YY Li","year":"1998","unstructured":"Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 1998;98:1728\u201334.","journal-title":"Circulation"},{"key":"10717_CR118","doi-asserted-by":"crossref","unstructured":"Lin H, Bin et al (2014) Inhibition of MMP-2 expression with siRNA increases baseline cardiomyocyte contractility and protects against simulated ischemic reperfusion injury. Biomed Res Int 2014","DOI":"10.1155\/2014\/810371"},{"key":"10717_CR119","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCRESAHA.114.303634","volume":"114","author":"JA Zavadzkas","year":"2014","unstructured":"Zavadzkas JA, et al. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res. 2014;114:1435\u201345.","journal-title":"Circ Res"},{"key":"10717_CR120","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jacc.2017.05.035","volume":"70","author":"T M\u00fcnzel","year":"2017","unstructured":"M\u00fcnzel T, et al. Impact of oxidative stress on the heart and vasculature: part 2 of a 3-part series. J Am Coll Cardiol. 2017;70:212\u201329.","journal-title":"J Am Coll Cardiol"},{"key":"10717_CR121","doi-asserted-by":"crossref","unstructured":"Song R, Hu XQ, Zhang L. Mitochondrial miRNA in cardiovascular function and disease. Cells. 2019.","DOI":"10.3390\/cells8121475"},{"key":"10717_CR122","doi-asserted-by":"crossref","unstructured":"Wang X et al. Mitochondria associated microRNA expression profiling of heart failure. Biomed Res Int. 2017.","DOI":"10.1155\/2017\/4042509"},{"key":"10717_CR123","doi-asserted-by":"crossref","unstructured":"Aoi W et al (2010) The microRNA miR-696 regulates PGC-1{alpha} in mouse skeletal muscle in response to physical activity. Am J Physiol Endocrinol Metab 298","DOI":"10.1152\/ajpendo.00448.2009"},{"key":"10717_CR124","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2006.09.024","volume":"127","author":"J St-Pierre","year":"2006","unstructured":"St-Pierre J, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127:397\u2013408.","journal-title":"Cell"},{"issue":"7","key":"10717_CR125","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41419-019-1734-7","volume":"10","author":"K Yan","year":"2019","unstructured":"Yan K, et al. Mitochondrial miR-762 regulates apoptosis and myocardial infarction by impairing ND2. Cell Death Dis. 2019;10(7):500.","journal-title":"Cell Death Dis."},{"key":"10717_CR126","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1016\/S0735-1097(03)00471-6","volume":"41","author":"C Heymes","year":"2003","unstructured":"Heymes C, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003;41:2164\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"10717_CR127","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.freeradbiomed.2005.08.010","volume":"40","author":"F Qin","year":"2006","unstructured":"Qin F, Patel R, Yan C, Liu W. NADPH oxidase is involved in angiotensin II-induced apoptosis in H9C2 cardiac muscle cells: effects of apocynin. Free Radic Biol Med. 2006;40:236\u201346.","journal-title":"Free Radic Biol Med"},{"key":"10717_CR128","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.freeradbiomed.2007.04.021","volume":"43","author":"F Qin","year":"2007","unstructured":"Qin F, Simeone M, Patel R. Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic Biol Med. 2007;43:271\u201381.","journal-title":"Free Radic Biol Med"},{"key":"10717_CR129","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.107.101980","volume":"51","author":"YH Looi","year":"2008","unstructured":"Looi YH, et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension. 2008;51:319\u201325.","journal-title":"Hypertension"},{"key":"10717_CR130","doi-asserted-by":"publisher","first-page":"7790","DOI":"10.1016\/j.biomaterials.2013.06.051","volume":"34","author":"I Somasuntharam","year":"2013","unstructured":"Somasuntharam I, et al. Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials. 2013;34:7790\u20138.","journal-title":"Biomaterials"},{"key":"10717_CR131","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.freeradbiomed.2006.07.010","volume":"41","author":"S Baldus","year":"2006","unstructured":"Baldus S, et al. Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. Free Radic Biol Med. 2006;41:1282\u20138.","journal-title":"Free Radic Biol Med"},{"key":"10717_CR132","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1161\/hc4501.098928","volume":"104","author":"TP Cappola","year":"2001","unstructured":"Cappola TP, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407\u201311.","journal-title":"Circulation"},{"key":"10717_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174368","volume":"908","author":"YS Zhang","year":"2021","unstructured":"Zhang YS, et al. Allopurinol attenuates oxidative injury in rat hearts suffered ischemia\/reperfusion via suppressing the xanthine oxidase\/vascular peroxidase 1 pathway. Eur J Pharmacol. 2021;908: 174368.","journal-title":"Eur J Pharmacol."},{"key":"10717_CR134","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbrc.2009.11.005","volume":"391","author":"J Ai","year":"2010","unstructured":"Ai J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010;391:73\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"10717_CR135","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12192-014-0565-9","volume":"20","author":"L Wang","year":"2015","unstructured":"Wang L, et al. Microrna-1 aggravates cardiac oxidative stress by post-transcriptional modification of the antioxidant network. Cell Stress Chaperones. 2015;20:411\u201320.","journal-title":"Cell Stress Chaperones"},{"key":"10717_CR136","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1158\/0008-5472.CAN-12-0639","volume":"72","author":"X Zhang","year":"2012","unstructured":"Zhang X, et al. Microrna-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNF\u03b1. Cancer Res. 2012;72:4707\u201313.","journal-title":"Cancer Res"},{"key":"10717_CR137","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1161\/ATVBAHA.118.311145","volume":"38","author":"V Joris","year":"2018","unstructured":"Joris V, et al. MicroRNA-199a-3p and MicroRNA-199a-5p take part to a redundant network of regulation of the NOS (NO synthase)\/NO pathway in the endothelium. Arterioscler Thromb Vasc Biol. 2018;38:2345\u201357.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10717_CR138","first-page":"71","volume":"21","author":"Q Wu","year":"2021","unstructured":"Wu Q, et al. MicroRNA-126 enhances the biological function of endothelial progenitor cells under oxidative stress via PI3K\/Akt\/GSK3\u03b2 and ERK1\/2 signaling pathways. Bosn J Basic Med Sci. 2021;21:71\u201380.","journal-title":"Bosn J Basic Med Sci"},{"key":"10717_CR139","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1071-9164(96)80047-9","volume":"2","author":"Y Seta","year":"1996","unstructured":"Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243\u20139.","journal-title":"J Card Fail"},{"key":"10717_CR140","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/01.CIR.93.4.704","volume":"93","author":"G Torre-Amione","year":"1996","unstructured":"Torre-Amione G, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704\u201311.","journal-title":"Circulation"},{"key":"10717_CR141","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","volume":"103","author":"A Deswal","year":"2001","unstructured":"Deswal A, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055\u20139.","journal-title":"Circulation"},{"key":"10717_CR142","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S0735-1097(96)00268-9","volume":"28","author":"M Testa","year":"1996","unstructured":"Testa M, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28:964\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"10717_CR143","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.amjcard.2019.09.036","volume":"125","author":"J van Wezenbeek","year":"2020","unstructured":"van Wezenbeek J, et al. Determinants of cardiorespiratory fitness in patients with heart failure across a wide range of ejection fractions. Am J Cardiol. 2020;125:76\u201381.","journal-title":"Am J Cardiol"},{"key":"10717_CR144","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","volume":"107","author":"RS Vasan","year":"2003","unstructured":"Vasan RS, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486\u201391.","journal-title":"Circulation"},{"key":"10717_CR145","doi-asserted-by":"crossref","unstructured":"Turner NA et al (2009) Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. Am J Physiol Heart Circ Physiol 297","DOI":"10.1152\/ajpheart.00372.2009"},{"key":"10717_CR146","doi-asserted-by":"crossref","unstructured":"Mitchell MD, Laird RE, Brown RD, Long CS (2007) IL-1beta stimulates rat cardiac fibroblast migration via MAP kinase pathways. Am J Physiol Heart Circ Physiol 292","DOI":"10.1152\/ajpheart.00881.2005"},{"key":"10717_CR147","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1161\/01.RES.86.12.1259","volume":"86","author":"DA Siwik","year":"2000","unstructured":"Siwik DA, Chang DLF, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res. 2000;86:1259\u201365.","journal-title":"Circ Res"},{"key":"10717_CR148","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","volume":"139","author":"BM Everett","year":"2019","unstructured":"Everett BM, et al. Anti-inflammatory therapy with Canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139:1289\u201399.","journal-title":"Circulation"},{"key":"10717_CR149","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331.","journal-title":"N Engl J Med"},{"key":"10717_CR150","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","volume":"117","author":"I Ikonomidis","year":"2008","unstructured":"Ikonomidis I, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117:2662\u20139.","journal-title":"Circulation"},{"key":"10717_CR151","doi-asserted-by":"publisher","first-page":"34590","DOI":"10.1074\/jbc.M109.056317","volume":"284","author":"MA Nahid","year":"2009","unstructured":"Nahid MA, Pauley KM, Satoh M, Chan EKL. miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J Biol Chem. 2009;284:34590\u20139.","journal-title":"J Biol Chem"},{"key":"10717_CR152","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood.2019002045","volume":"135","author":"YL Su","year":"2020","unstructured":"Su YL, et al. Myeloid cell-targeted miR-146a mimic inhibits NF-\u03baB-driven inflammation and leukemia progression in vivo. Blood. 2020;135:167\u201380.","journal-title":"Blood"},{"key":"10717_CR153","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.7150\/thno.42982","volume":"10","author":"G Shen","year":"2020","unstructured":"Shen G, et al. Mir-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss. Theranostics. 2020;10:4334\u201348.","journal-title":"Theranostics"},{"key":"10717_CR154","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3171\/2017.5.JNS163165","volume":"130","author":"YS Tian","year":"2019","unstructured":"Tian YS, et al. Upregulation of miR-216a exerts neuroprotective effects against ischemic injury through negatively regulating JAK2\/STAT3-involved apoptosis and inflammatory pathways. J Neurosurg. 2019;130:977\u201388.","journal-title":"J Neurosurg"},{"key":"10717_CR155","volume":"8","author":"J Li","year":"2020","unstructured":"Li J, He W, Wang Y, Zhao J, Zhao X. MiR-103a-3p alleviates oxidative stress, apoptosis, and immune disorder in oxygen-glucose deprivation-treated BV2 microglial cells and rats with cerebral ischemia-reperfusion injury by targeting high mobility group box 1. Ann Transl Med. 2020;8:1296\u20131296.","journal-title":"Ann Transl Med"},{"key":"10717_CR156","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086800","author":"S Lorente-Cebri\u00e1n","year":"2014","unstructured":"Lorente-Cebri\u00e1n S, et al. Micrornas regulate human adipocyte lipolysis: effects of miR-145 are linked to TNF-\u03b1. PLoS ONE. 2014;9(1):e86800.","journal-title":"PLoS ONE"},{"key":"10717_CR157","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","volume":"103","author":"A Deswal","year":"2001","unstructured":"Deswal A, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055\u20139.","journal-title":"Circulation"},{"key":"10717_CR158","doi-asserted-by":"crossref","unstructured":"Mitchell MD, Laird RE, Brown RD, Long CS (2007) IL-1beta stimulates rat cardiac fibroblast migration via MAP kinase pathways. Am J Physiol Heart Circ Physiol 292","DOI":"10.1152\/ajpheart.00881.2005"},{"key":"10717_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-023-03232-8","volume":"22","author":"M Fu","year":"2024","unstructured":"Fu M, et al. Single-cell RNA sequencing in donor and end-stage heart failure patients identifies NLRP3 as a therapeutic target for arrhythmogenic right ventricular cardiomyopathy. BMC Med. 2024;22:1\u201320.","journal-title":"BMC Med"},{"issue":"8","key":"10717_CR160","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/ni.2072","volume":"12","author":"D Baltimore","year":"2011","unstructured":"Baltimore D. NF-\u03baB is 25. Nat Immunol. 2011;12(8):683\u20135.","journal-title":"Nat Immunol"},{"key":"10717_CR161","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1172\/JCI61716","volume":"122","author":"M Nazari-Jahantigh","year":"2012","unstructured":"Nazari-Jahantigh M, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest. 2012;122:4190\u2013202.","journal-title":"J Clin Invest"},{"key":"10717_CR162","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1038\/onc.2008.171","volume":"27","author":"D Bhaumik","year":"2008","unstructured":"Bhaumik D, et al. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008;27:5643\u20137.","journal-title":"Oncogene"},{"key":"10717_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077249","author":"M Garg","year":"2013","unstructured":"Garg M, Potter JA, Abrahams VM. Identification of micrornas that regulate TLR2-mediated trophoblast apoptosis and inhibition of IL-6 mRNA. PLoS ONE. 2013;8(10):e77249.","journal-title":"PLoS ONE"},{"key":"10717_CR164","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0008-6363(99)00262-X","volume":"45","author":"JK Dam\u00e5s","year":"2000","unstructured":"Dam\u00e5s JK, et al. CXC-chemokines, a new group of cytokines in congestive heart failure\u2013possible role of platelets and monocytes. Cardiovasc Res. 2000;45:428\u201336.","journal-title":"Cardiovasc Res"},{"key":"10717_CR165","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1161\/01.CIR.102.11.1315","volume":"102","author":"TM Behr","year":"2000","unstructured":"Behr TM, et al. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation. 2000;102:1315\u201322.","journal-title":"Circulation"},{"key":"10717_CR166","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0002-9440(10)62568-0","volume":"160","author":"NG Frangogiannis","year":"2002","unstructured":"Frangogiannis NG, et al. Evidence for an active inflammatory process in the hibernating human myocardium. Am J Pathol. 2002;160:1425\u201333.","journal-title":"Am J Pathol"},{"key":"10717_CR167","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1006\/cyto.1998.0354","volume":"10","author":"MH Lehmann","year":"1998","unstructured":"Lehmann MH, K\u00fchnert H, M\u00fcller S, Sigusch HH. Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy. Cytokine. 1998;10:739\u201346.","journal-title":"Cytokine"},{"key":"10717_CR168","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.carpath.2008.12.004","volume":"18","author":"J Iwasaki","year":"2009","unstructured":"Iwasaki J, et al. Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2009;18:317\u201322.","journal-title":"Cardiovasc Pathol"},{"key":"10717_CR169","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1161\/CIRCULATIONAHA.105.572396","volume":"112","author":"S G\u00f6ser","year":"2005","unstructured":"G\u00f6ser S, et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation. 2005;112:3400\u20137.","journal-title":"Circulation"},{"key":"10717_CR170","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1093\/eurheartj\/ehu225","volume":"36","author":"F Leuschner","year":"2015","unstructured":"Leuschner F, et al. Silencing of CCR2 in myocarditis. Eur Heart J. 2015;36:1478\u201388.","journal-title":"Eur Heart J"},{"key":"10717_CR171","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clim.2009.04.008","volume":"134","author":"Z Kaya","year":"2010","unstructured":"Kaya Z, Katus HA, Rose NR. Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure. Clin Immunol. 2010;134:80\u20138.","journal-title":"Clin Immunol"},{"key":"10717_CR172","doi-asserted-by":"publisher","first-page":"94069","DOI":"10.18632\/oncotarget.21578","volume":"8","author":"H Wang","year":"2017","unstructured":"Wang H, Xu W, Shao Q, Ding Q. Mir-21 silencing ameliorates experimental autoimmune encephalomyelitis by promoting the differentiation of IL-10-producing B cells. Oncotarget. 2017;8:94069\u201379.","journal-title":"Oncotarget"},{"key":"10717_CR173","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01555-7","author":"G Meng","year":"2020","unstructured":"Meng G, Wei J, Wang Y, Qu D, Zhang J. MiR-21 regulates immunosuppression mediated by myeloid-derived suppressor cells by impairing RUNX1-YAP interaction in lung cancer. Cancer Cell Int. 2020;20:495.","journal-title":"Cancer Cell Int"},{"key":"10717_CR174","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s10753-020-01298-7","volume":"43","author":"Q Zou","year":"2020","unstructured":"Zou Q, Yang M, Yu M, Liu C. Influences of regulation of miR-126 on inflammation, Th17\/Treg subpopulation differentiation, and lymphocyte apoptosis through caspase signaling pathway in sepsis. Inflammation. 2020;43:2287\u2013300.","journal-title":"Inflammation"},{"key":"10717_CR175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.55676","volume":"9","author":"X Zhang","year":"2020","unstructured":"Zhang X, Liu J, Wu L, Hu X. Micrornas of the miR-17~9 family maintain adipose tissue macrophage homeostasis by sustaining IL-10 expression. Elife. 2020;9:1\u201319.","journal-title":"Elife"},{"key":"10717_CR176","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"10717_CR177","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/nat.2020.0845","volume":"30","author":"A Aartsma-Rus","year":"2020","unstructured":"Aartsma-Rus A, Corey DR. The 10th oligonucleotide therapy approved: Golodirsen for Duchenne muscular dystrophy. Nucleic Acid Ther. 2020;30:67.","journal-title":"Nucleic Acid Ther"},{"key":"10717_CR178","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.3390\/ijms23052427","volume":"23","author":"TR Eijgenraam","year":"2022","unstructured":"Eijgenraam TR, et al. Antisense therapy attenuates phospholamban p.(Arg14del) cardiomyopathy in mice and reverses protein aggregation. Int J Mol Sci. 2022;23:2427.","journal-title":"Int J Mol Sci"},{"key":"10717_CR179","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.phrs.2016.05.008","volume":"110","author":"J Hullmann","year":"2016","unstructured":"Hullmann J, Traynham CJ, Coleman RC, Koch WJ. The expanding GRK interactome: implications in cardiovascular disease and potential for therapeutic development. Pharmacol Res. 2016;110:52\u201364.","journal-title":"Pharmacol Res"},{"key":"10717_CR180","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1124\/jpet.121.001251","volume":"384","author":"P Mone","year":"2023","unstructured":"Mone P, et al. Empagliflozin improves the MicroRNA signature of endothelial dysfunction in patients with heart failure with preserved ejection fraction and diabetes. J Pharmacol Exp Ther. 2023;384:116\u201322.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10717-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:03:09Z","timestamp":1765555389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10717-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":180,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10717"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10717-9","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and Consent to Participate"}},{"value":"Frederik E. Deiman, Myrthe M. de Graaf, Nils B\u00f6mer, and Niels Grote Beverborg declare no conflict of interest. Herman H.W. Sillj\u00e9 reports grants from AstraZeneca, Novo Nordisk and Pfizer, outside the submitted work. Peter van der Meer reports grants from Ionis Pharmaceuticals, AstraZeneca, Novo Nordisk, Pfizer, Vifor Pharma, and Pharma Nord, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}